Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma
about
Identification of a novel contactin-associated transmembrane receptor with multiple domains implicated in protein-protein interactions.Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase IINeural expression and chromosomal mapping of Neu differentiation factor to 8p12-p21A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factorHER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancerPhosphorylation sites at the C-terminus of the platelet-derived growth factor receptor bind phospholipase C gamma 1ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancerEmerging therapies in gastrointestinal cancers.Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationshipsHeterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation.Specific epidermal growth factor receptor autophosphorylation sites promote mouse colon epithelial cell chemotaxis and restitution.Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity.Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growthTransmembrane domain sequence requirements for activation of the p185c-neu receptor tyrosine kinase.PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu.Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.Interspecies molecular chimeras of kit help define the binding site of the stem cell factor.Interkinase domain of kit contains the binding site for phosphatidylinositol 3' kinase.HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway.LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.Activation of phospholipase C gamma in Schizosaccharomyces pombe by coexpression of receptor or nonreceptor tyrosine kinases.Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy.
P2860
Q24316000-D09922F2-8F14-4D01-B953-4330573503DEQ24551154-A4A8667E-065E-4F97-81A7-172029515708Q24563427-6906B6D5-C77B-477C-8538-0AF36590F6D2Q24648517-7F2A2BF4-CC04-45E1-8F2C-727CAB59BA42Q28085413-0852AE52-7422-4300-B02A-DDD2D66B402DQ28645716-A7CDAFDD-9918-4B15-AEDB-CFFE36DACACFQ28678776-8A460A12-9210-45F3-8888-47F647202ABAQ33866870-BC4A7AFB-B818-4C8F-A4C2-725F83FA7825Q34045509-C0484BD7-265B-447A-A683-0CD1BE110CD9Q35054357-AD449172-F61A-4199-A46A-6AA9E8DD327BQ35159605-EA274937-3DD0-458C-99E3-7D90514DE9FCQ35325158-3AA3FE99-17EE-46A1-976C-318E0EFD35B5Q35977584-A24F768E-2758-4BCC-A69A-E75B8FA403A9Q36274097-C10D1FCD-CE2A-4F03-B160-A766C4D61E86Q36365039-BB9AA871-E956-47BA-A126-937879512488Q36544650-206677BD-0976-4FF7-A51D-81BF3423B7F9Q36678155-09A6ADFC-50FA-4B71-B945-F0F0ECCEAFBFQ36794090-8652ED3F-06AF-442D-9312-9D84FDE46A66Q37380727-8E369705-9708-4DAC-BB2D-80151BC29377Q37634563-632E84AC-AF1C-4059-9C98-40974C8E13ACQ39817827-C7E417D6-1373-430A-86CA-843217CCEC64Q40015802-596C69CC-0404-4F3C-B7F4-8AEE0DA50C22Q42025768-8BA2BDDC-1A1C-4C0C-8093-F61D692FEA38
P2860
Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma
description
1991 nî lūn-bûn
@nan
1991 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Oncogenic forms of the neu/HER ...... upled to phospholipase C gamma
@ast
Oncogenic forms of the neu/HER ...... upled to phospholipase C gamma
@en
Oncogenic forms of the neu/HER ...... upled to phospholipase C gamma
@nl
type
label
Oncogenic forms of the neu/HER ...... upled to phospholipase C gamma
@ast
Oncogenic forms of the neu/HER ...... upled to phospholipase C gamma
@en
Oncogenic forms of the neu/HER ...... upled to phospholipase C gamma
@nl
prefLabel
Oncogenic forms of the neu/HER ...... upled to phospholipase C gamma
@ast
Oncogenic forms of the neu/HER ...... upled to phospholipase C gamma
@en
Oncogenic forms of the neu/HER ...... upled to phospholipase C gamma
@nl
P2093
P2860
P1433
P1476
Oncogenic forms of the neu/HER ...... upled to phospholipase C gamma
@en
P2093
P2860
P304
P407
P577
1991-08-01T00:00:00Z